Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Gains from Sales and Divestitures (2020 - 2022)

Relay Therapeutics (RLAY) reported Gains from Sales and Divestitures of $398330.0 for Q4 2022, up 424.98% year-over-year from $75875.0 in Q4 2021, and up 424.98% on a QoQ basis from $75875.0 in Q4 2021.

Relay Therapeutics (RLAY) has 3 years of Gains from Sales and Divestitures data on file, last reported at $398330.0 in Q4 2022.

  • Quarterly Gains from Sales and Divestitures rose 424.98% year-over-year to $398330.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $398330.0 (up 424.98% YoY) and the FY2022 annual result came in at $398330.0, up 424.98% from the prior year.
  • Gains from Sales and Divestitures rose to $398330.0 in Q4 2022 per RLAY's latest filing, from $75875.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $579825.0 in Q4 2020 and bottomed at $75875.0 in Q4 2021.
  • The 3-year median for Gains from Sales and Divestitures is $398330.0 (2022), against an average of $351343.3.
  • The widest annual swing landed in 2021, when Gains from Sales and Divestitures sank 86.91%; it then jumped 424.98% in 2022.
  • Tracing RLAY's Gains from Sales and Divestitures over 3 years: stood at $579825.0 in 2020, then slumped by 86.91% to $75875.0 in 2021, then jumped by 424.98% to $398330.0 in 2022.
  • Per Business Quant, the three latest RLAY Gains from Sales and Divestitures figures stand at $398330.0 (Q4 2022), $75875.0 (Q4 2021), and $579825.0 (Q4 2020).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Relay Therapeutics 2.53 Bn 2.53 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 398,330.00
Dec 31, 2022 398,330.00
Dec 31, 2021 75,875.00
Dec 31, 2021 75,875.00
Dec 31, 2020 579,825.00
Dec 31, 2020 579,825.00